{{Rsnum
|rsid=2304016
|Gene=SCN2A
|Chromosome=2
|position=165311993
|Orientation=plus
|GMAF=0.03168
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SCN2A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 97.2 | 2.8 | 0.0
| HCB | 68.9 | 28.9 | 2.2
| JPT | 82.2 | 17.8 | 0.0
| YRI | 98.6 | 1.4 | 0.0
| ASW | 98.1 | 1.9 | 0.0
| CHB | 68.9 | 28.9 | 2.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 99.0 | 1.0 | 0.0
| LWK | 97.2 | 2.8 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs2304016]] (IVS7-32A>G) is a SNP within the [[SCN2A]] (sodium channel, voltage-gated, type II, alpha subunit).

{{PMID|18784617}} among 471 Chinese epilepsy patients (of which 272 were drug responsive and 199 drug resistant), A-allele carriers associated with resistance to anti-epileptic drugs (OR 2.1, 95% CI 1.2-3.7, p=0.007), haplotypes containing A-alleles were also associated w/ drug resistance

{{PharmGKB
|RSID=rs2304016
|Name_s=SCN2A:IVS7-32A>G
|Gene_s=SCN2A2, SCN2A
|Feature=
|Evidence=PubMed ID:18784617
|Annotation=The A allele of this SNP was associated with resistance to sodium channel-blocking anti-epileptic drugs in a Chinese patient population.
|Drugs=carbamazepine; lamotrigine; oxcarbazepine; phenytoin; topiramate
|Drug Classes=
|Diseases=Epilepsy
|Curation Level=Curated
|PharmGKB Accession ID=PA162361063
}}

{{PMID Auto
|PMID=22569204
|Title=PharmGKB summary: phenytoin pathway.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2304016
|overall_frequency_n=12
|overall_frequency_d=10754
|overall_frequency=0.00111586
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=4
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}